Fundraising FoxVersant Venture Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)inJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)
BoardMonal Mehta(Director)inAli Behbahani(Director)in
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.